Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L A Janssen

Showing results (11-20 of 612) with videos related to

Pageof 62
Sort By:
Alimentary Pharmacology & Therapeutics|February 13, 2019
Editorial: identifying candidates for pegylated interferon add-on to entecavir therapy in patients with HBeAg-positive chronic hepatitis B - authors' replyKin Seng Liem, Harry L A Janssen
Journal of Hepatology|December 15, 2025
Individualizing endpoints in chronic HBV treatment: HBsAg loss and beyondMilan J Sonneveld, Harry L A Janssen
Current Hepatitis Reports|May 13, 2010
Pros and Cons of Peginterferon Versus Nucleos(t)ide Analogues for Treatment of Chronic Hepatitis BMilan J Sonneveld, Harry L A Janssen
Journal of Hepatology|January 15, 2013
Reply to: "Identification of chronic hepatitis B"Irene K Veldhuijzen, Harry L A Janssen
Hepatology (Baltimore, Md.)|March 5, 2024
Letter to the Editor: Provider preparedness for functional cure of chronic hepatitis BRobert P Perrillo, Harry L A Janssen
The New England Journal of Medicine|January 8, 2025
Combination Therapy for Chronic HBV InfectionHarry L A Janssen, Milan J Sonneveld
Journal of Hepatology|December 1, 2024
Reply to: "The incidence of hepatitis flare and hepatic decompensation after nucleos(t)ide analogue cessation in chronic hepatitis B patients"Edo J Dongelmans, Harry L A Janssen
The New England Journal of Medicine|August 22, 2006
Case 15-2006: the Budd-Chiari syndrome and V617F mutation in JAK2Sarwa Darwish Murad, Harry L A Janssen
Liver International : Official Journal of the International Association for the Study of the Liver|January 6, 2011
Chronic hepatitis B: peginterferon or nucleos(t)ide analogues?Milan J Sonneveld, Harry L A Janssen
Journal of Hepatology|March 13, 2026
Is Partial Cure a Realistic Endpoint for Novel Hepatitis B Therapy? Reply to Chan et alMilan J Sonneveld, Harry L A Janssen
Pageof 62

Showing results (11-20 of 612) with videos related to

Sort By:
Pageof 62
Alimentary Pharmacology & Therapeutics|February 13, 2019
Editorial: identifying candidates for pegylated interferon add-on to entecavir therapy in patients with HBeAg-positive chronic hepatitis B - authors' replyKin Seng Liem, Harry L A Janssen
Journal of Hepatology|December 15, 2025
Individualizing endpoints in chronic HBV treatment: HBsAg loss and beyondMilan J Sonneveld, Harry L A Janssen
Current Hepatitis Reports|May 13, 2010
Pros and Cons of Peginterferon Versus Nucleos(t)ide Analogues for Treatment of Chronic Hepatitis BMilan J Sonneveld, Harry L A Janssen
Journal of Hepatology|January 15, 2013
Reply to: "Identification of chronic hepatitis B"Irene K Veldhuijzen, Harry L A Janssen
Hepatology (Baltimore, Md.)|March 5, 2024
Letter to the Editor: Provider preparedness for functional cure of chronic hepatitis BRobert P Perrillo, Harry L A Janssen
The New England Journal of Medicine|January 8, 2025
Combination Therapy for Chronic HBV InfectionHarry L A Janssen, Milan J Sonneveld
Journal of Hepatology|December 1, 2024
Reply to: "The incidence of hepatitis flare and hepatic decompensation after nucleos(t)ide analogue cessation in chronic hepatitis B patients"Edo J Dongelmans, Harry L A Janssen
The New England Journal of Medicine|August 22, 2006
Case 15-2006: the Budd-Chiari syndrome and V617F mutation in JAK2Sarwa Darwish Murad, Harry L A Janssen
Liver International : Official Journal of the International Association for the Study of the Liver|January 6, 2011
Chronic hepatitis B: peginterferon or nucleos(t)ide analogues?Milan J Sonneveld, Harry L A Janssen
Journal of Hepatology|March 13, 2026
Is Partial Cure a Realistic Endpoint for Novel Hepatitis B Therapy? Reply to Chan et alMilan J Sonneveld, Harry L A Janssen
Pageof 62